Healthcare is moving in two directions at once.
Medicine is becoming more technologically sophisticated. And patients increasingly expect it to become more personal.
Those trends are not contradictory. They are the same trend.
As diagnostics improve, longitudinal health data become easier to interpret, and AI gives clinicians better tools for organizing complex information, it becomes harder to defend the idea that every patient should receive exactly the same intervention in exactly the same format.
That is where individualized care — and, in appropriate circumstances, pharmacy compounding — becomes interesting.
What is a 503A pharmacy?
"503A" refers to Section 503A of the Federal Food, Drug, and Cosmetic Act.
In simplified terms, it establishes conditions under which a licensed pharmacist in a state-licensed pharmacy, a federal facility, or a licensed physician may compound medication for an identified individual patient pursuant to a valid prescription while qualifying for certain exemptions that apply to conventionally manufactured drugs.
The key phrase is individual patient.
503A is fundamentally different from an anonymous website manufacturing thousands of identical vials and selling them directly to anyone with a credit card.
A clinician evaluates a patient. A prescription is issued when appropriate. And the pharmacy prepares and dispenses the compounded medication within the framework that applies to it.
Why would anyone need a compounded medication?
Because patients are not interchangeable.
FDA itself gives straightforward examples. A patient may need a medication without a particular dye because of an allergy. A child or older adult may require a liquid because they cannot swallow the commercially available tablet.
In those situations, compounding can meet a legitimate clinical need that the standardized commercial product does not.
The same conceptual principle becomes increasingly relevant as medicine becomes more individualized: start with the patient, then determine the appropriate intervention. Not the other way around.
What 503A does not mean
This is just as important.
A compounded drug is not an FDA-approved drug.
FDA does not review and approve each compounded product for safety, effectiveness and quality before it reaches the market in the way it does with an approved branded or generic pharmaceutical. FDA explicitly makes that distinction.
Nor is a traditional 503A pharmacy the same thing as a 503B outsourcing facility.
State boards of pharmacy generally have primary day-to-day oversight of state-licensed pharmacies operating under 503A, although FDA retains authority and conducts surveillance and for-cause inspections. 503A products also are not subject to the same CGMP requirements that apply to conventional drug manufacturers and 503B outsourcing facilities when the statutory conditions are satisfied.
That transparency matters.
Compliance should never be communicated by making the regulatory framework sound stronger than it actually is. It should be communicated by explaining what the framework really requires — and then exceeding the minimum wherever possible.
Not every ingredient can simply be compounded
503A is also not a blank check to compound any molecule a patient requests.
Federal law restricts the bulk drug substances that may be used. Depending on the substance, eligibility can relate to an applicable USP or NF monograph, whether the substance is a component of an FDA-approved drug, or inclusion on the 503A Bulks List. FDA also maintains interim policies for certain nominated substances while evaluations continue.
The regulatory status of specific peptide substances remains especially dynamic in 2026. FDA's July Pharmacy Compounding Advisory Committee process considered several peptide-related bulk substances, while FDA staff simultaneously raised significant characterization and safety questions about a number of them.
That is why a responsible platform does not treat "peptide" as a regulatory category. Each molecule, route, formulation and current legal status has to be evaluated independently.
So where does LegitScript fit?
LegitScript is different again. It is not the FDA. It is not a state board of pharmacy. And its certification is not government approval of a medication.
Instead, LegitScript provides an independent healthcare merchant certification used widely across the digital healthcare ecosystem.
Its current standards evaluate areas including appropriate licensing, jurisdictional compliance, prescription and telemedicine practices, patient services, business relationships, privacy, transparency and advertising. Certification is also relevant to access to major advertising and payment platforms.
That makes it a useful additional trust signal.
But the right way to communicate it is precisely this: it adds another layer of independent compliance review. It does not replace pharmacy licensure, clinical responsibility or FDA requirements.
Personalized medicine without personalized chaos
There is an obvious danger in talking about personalized healthcare. "Personalized" can become another euphemism for doing whatever somebody wants.
That is not the future Prism believes in.
Real personalization should be more disciplined than standardized medicine, not less.
It should incorporate medical history. Current medications. Symptoms. Objective laboratory data where clinically useful. Risk factors. Therapeutic goals. Contraindications. Response over time. And a clear clinical reason for selecting one intervention rather than another.
AI will make parts of that process dramatically easier. A clinician can increasingly work with systems capable of organizing years of laboratory results, identifying longitudinal changes, surfacing medication conflicts, comparing symptoms with objective data and highlighting information that deserves closer review.
But AI should strengthen clinical decision-making, not eliminate it. The final decision still belongs inside a legitimate clinician-patient relationship.
What Prism is building around 503A
Our interest in 503A is not simply that it offers a faster path to market. The more important opportunity is what it allows us to build around it.
Prism's model separates the critical responsibilities: clinical evaluation and prescribing sit with licensed healthcare professionals; pharmacy compounding and dispensing sit with the pharmacy; and Prism provides the technology, formulation and patient-facing infrastructure around that care model.
That architecture creates a foundation for something much bigger: personalized medicine that can actually scale.
Not self-prescribed research chemicals. Not an identical "peptide stack" handed to everyone who visits a website. And not AI pretending to be a physician.
A system where sophisticated technology makes it easier for a real clinician to understand the individual in front of them — and where the medication, dose, delivery format and follow-up can be adapted accordingly when the law and clinical evidence support it.
That is a version of personalized medicine worth building.
